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Epigenetic Effects of Liver Tumor
Promoters and Implications for Health
Effects
by Gary M. Williams*
During chemical carcinogenesis in the liver, a population of abnormal cells in lesions referred to
as altered foci precedes the appearance of neoplasms. Most altered foci do not develop further, but a
small fraction progress to formation of neoplasms. Liver tumor promoters increase the fraction that
progress.
The mechanisms for this action of promoters may involve an effect on the cell membrane. Cells in
vivo and in vitro exchange molecules through specialized membrane organelles known as gap junc-
tions. Intercellular transfer of growth and/or differentiation regulating factors could be involved in
suppressing the growth of initiated cells in the altered foci. Several liver tumor promoters have
been found to inhibit intercellular communication in an in vitro liver culture system. This effect on
the cell membrane could, thus, be the basis for the release of cells in foci for further growth into
neoplasms. Such an epigenetic action would account for the requirement for high doses and pro-
longed exposure for certain liver tumor promoters. In addition, it implies a distinct type of health
risk analysis for chemicals of this type.
Several chemicals, particularly halogenated hydrocarbons, produce primarily or exclusively an
increase in liver tumors in rodent strains that are characterized by a substantial background inci-
dence of such tumors. These chemicals have not been demonstrated to have the DNA damaging ca-
pability of genotoxic carcinogens and several enhance the hepatocarcinogenicity of previously ad-
ministered liver carcinogens. Moreover, they exert an inhibition of intercellular communication.
Thus, carcinogens of this type may be epigenetic carcinogens functioning as liver tumor promoters.
Accordingly, the health risk analysis for these chemicals is different from that for genotoxic carcin-
ogens.
Introduction
A tumor promoter is an agent that facilitates for-
mation of neoplasms from altered cells that other-
wise would remain dormant. Although tumor pro-
moters are usually identified by their enhancement
of the tumor yield resulting from a previously ad-
ministered carcinogen, called an "initiating" agent
in the terminology adopted for two-stage carcino-
genesis (1), they can also be conceived to promote
tumor formation by cells altered through effects
other than experimentally induced initiation, such
as cells with an inherited genetic abnormality or a
spontaneous mutation.
Two general schemes shown in Figure 1 have
been postulated for the process of promotion: (1)
promoters could complete the conversion of par-
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FIGURE 1. Schemes for the action of tumor promoters.
tially transformed cells to fully neoplastic cells
(scheme A) which would then be capable of progres-
sive growth into tumors; (2) promoters could act on
dormant neoplastic cells to enable them to prolifer-
ate into overt neoplasms (scheme B) increasing the
incidence of tumors over that which would occur in
the absence of promotion.
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somehow render permanent neoplastic conversion
has been supported by reports of their effects on
cell differentiation (2-4) and genetic organization (5,
6). Such effects, however, thus far have been demon-
strated only for skin tumor promoters, phorbol es-
ters and teleocidin B (7). These agents function at
very low doses and have almost hormonelike char-
acteristics. In fact, Weinstein et al. (8) have sug-
gested that this class of promoters may act by
usurping the action of endogenous hormone or
growth regulatory substances. In a somewhat dif-
ferent version of the hypothesis of conversion of ini-
tiated cells to neoplastic cells by promoters, Bout-
well and associates (9) have proposed that skin tu-
mor promoters induce the neoplastic phenotype in
all epidermal cells and that this phenotype cannot
be reversed in the defective initiated cells.
Some liver tumor promoters induce enzyme ac-
tivities, reflecting a modulation of gene expression,
but they do not produce the effects on differentia-
tion and chromosomes reported for phorbol esters.
Thus, no substantial evidence exists for any action
at the level of genetic organization that might lead
to completion of neoplastic conversion by agents
that function as tumor promoters for this organ.
The second possible means by which promoters
may operate, i.e., by assisting dormant neoplastic
cells to form tumors corresponds to the original con-
cept of Berenblum (1). According to this hypothesis,
a tumor promoter enables the growth into tumors
of carcinogen-altered cells that otherwise would re-
main latent. This effect could be achieved through a
variety of mechanisms resulting either in selective
stimulation of proliferation in dormant neoplastic
cells or their release from controlling elements. Re-
cently, through the work of Trosko and associates
(10-12) and Murray and Fitzgerald (13), a cellular
effect of promoters which could produce a liberation
of initiated cells from tissue regulatory controls has
been identified.
Inhibition of Intercellular
Communication as a Mechanism
of Tumor Promotion
For some years, interest has focused on the ef-
fects of promoters on cell membranes (14-17), and a
variety of hypothesis have been advanced to ac-
count for tumor promotion on the basis of such ef-
fects. Yotti et al. (10) and Murray and Fitzgerald (13)
discovered the ability of tumor promoters to inhibit
cell membrane-mediated intercellular communica-
tion in fibroblast cell cultures. Williams and col-
leagues subsequently documented this action in
liver cell cultures for the liver tumor promoters,
phenobarbital (18) and DDT (19). Inhibition of cell-
cell communication represents an action that could
account for the characteristics of tumor promotion
in the liver.
Intercellular communication involving transmis-
sion of molecules between cells occurs through
membrane organelles known as gap junctions (20-
22). This process can be measured in cell culture as
the phenomenon of metabolic cooperation (cross
feeding) in which a lethal metabolite generated from
a precursor by one cell type is transferred to a mu-
tant that cannot produce it; as a result, the mutant,
which otherwise would be resistant to the effects of
addition of the precursor, is passively killed. For ex-
ample, hepatocytes possess the purine salvage path-
way enzyme, hypoxanthine-guanine phosphoribosyl
transferase, which is required to metabolize the syn-
thetic purine analog 6-thioguanine (TG) to a toxic
metabollte. Consequently, TG is lethal to hepato-
cytes. In contrast, a strain of 6-thioguanine resistant
TGr mutant adult rat liver cells selected by its resis-
tance to TG lacks HGPRT and is not affected by TG
(23) unless the metabolite is transferred to it
through metabolic cooperation. In a mixed culture
system, the lethal phosphoribosylated metabolite of
TG can be transferred from freshly isolated hepato-
cytes to the TGr mutant cells thereby killing them.
In this system, the degree of metabolic cooperation
is evidenced by the reduction in colony formation of
TGr cells cocultivated with hepatocytes in primary
culture. As Trosko and associates have described in
their cell system (12), inhibition of metabolic cooper-
ation by promoters can then be measured by resto-
ration of colony formation of the mutants. The use
of isolated hepatocytes in the present system is ad-
vantageous because they presumably retain ele-
ments of in vivo cell characteristics which might be
essential for a response to promoters and, of practi-
cal value, they are incapable of colony formation in
primary culture and thus do not interfere with the
determination of colony formation by the target
TGr cells.
The inhibition of metabolic cooperaton between
hepatocytes and adult rat liver epithelial- TGr cells
by the liver tumor promoter DDT is shown in Table
1. A similar effect is displayed by phenobarbital (18)
and heptachlor and chlordane (Table 2). The latter
two organochlorine pesticides have not yet been
demonstrated to be promoters, but have character-
istics which suggest that they would act as such
(24).
Inhibition of cell-cell communication in vitro, al-
though not perfectly correlated with promoting ac-
tivity (25), is the only property that has been demon-
strated for a variety of tumor promoters (10-12, 18,
19,25,26).
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The inhibition of intercellular communication be-
tween cultured liver cells by promoters could corre-
spond to an in vivo effect that would account for
liver tumor promotion. Cell proliferation in all tis-
sues is a precisely controlled process in which the
production of new cells balances those lost through
differentiation or death. The regulation of this pro-
cess is incompletely understood, but could involve
cell to cell transfer of factors that regulate growth,
including growth factors, chalones and other sub-
stances that induce differentiation and thereby, loss
of proliferative capability. Several lines of evidence
indicate that differentiation/growth regulation is ex-
erted on neoplastic cells. Most significantly, an in-
terval of up to one year can be allowed between ini-
tiation and the beginning of promotion with essen-
tially the same incidence of tumors occurring as
when promotion immediately follows initiation (27).
It seems certain that during the lengthy interval
between initiation and promotion, neoplastic cells
persist in the tissue along with normal cells and are
kept under control by the regulatory factors that
operate on normal cells.
In rodent liver during carcinogenesis by chemi-
cals, an abnormal population of cells in lesions re-
ferred to altered foci appears early in the process,
preceding the development of neoplasms. These foci
(Fig. 2) can be identified by a variety of phenotypic
abnormalities (28), including a reduced ability ac-
cumulate cellular iron (Fig. 3), and thereby can be
readily studied quantitatively (29). Under some con-
Table 1. Inhibition of metabolic cooperation
between hepatocytes and an ARL TGr strain by
a liver tumor promoter DDT.a
Condition TGr colonies per flaskb
No HPC 0.75 x 10' HPC
ARL 14-TGr 126 7 -
+ TG 110± 3 63± 10
+ TG + DDT 10-7 103 9 86 ± 4
+ TG + DDT 10' 101 13 112 ± 10
+ TG + DDT 10-5 105±11 117± 6
aFrom Williams et al. (19).
b500 TGr cells were cocultured with 0.75 x 10' HPC.
Values are the average of three flasks. Results are means ±
SD for triplicate determinations.
ditions, in the absence of promotion less than one in
a hundred of these altered foci will progress to tu-
mor formation (30); thus these foci appear to be un-
der strong regulatory control. Other examples of
the control of neoplastic cells are the induction of
differentiation in cells receiving a transplanted nu-
cleus from a neoplastic cell (31), in neoplastic cells
associated with normal embryonic cells in utero (32,
33) and in neoplastic cells exposed to embryo ex-
tracts (34, 35). If the control of dormant neoplastic
cells can be mediated by intercellular communica-
tion, as seems likely, then inhibition of communica-
FIGURE 2. Altered focus (arrows) in rat liver induced by N-2-
fluorenylacetamide. Hematoxylin and eosin, x 125.
Table 2. Inhibition of metabolic cooperation between hepatocytes and an ARL TGr strain by Chlordane and Heptachlor.
Condition ARL 14-TGrcolonies per flaska
No hepatocytes 1.25 x 10' Hepatocytes
TG 186a 87
TG + 5 x 106Chlordane 181 155
TG 146 55
TG + 1 x 10-6 Heptachlor 156 105
aResults are means of triplicate determinations.G. M. WILLIAMS
tion could release the neoplastic cells for the pro-
gressive growth that results in the formation of
neoplasms. In this manner, the inhibition of inter-
cellular communication could be one basis for tumor
promotion.
The liver-altered foci induced by carcinogens are
stimulated for further development by liver tumor
promoters (30, 36, 37). The enchancement of devel-
opment of these foci, as shown in Figure 4 for phe-
nobarbital (30), may result from the inhibition by tu-
mor promoters of transmission ofregulatory factors
from normal cells to the altered cells.
The inhibition of intercellular communication by
promoters can conceivably be produced in several
ways. Because of the lipophilicity of DDT and other
organochlorine compounds, they may accumulate in
the lipid layer of the liver cell membranes and di-
rectly interfere with the function of gap junctions.
The means of inhibition by phenobarbital may be
more complex. Phenobarbital affects the hepatic ac-
tivity of several membrane-associated enzymes (38,
39) and recently, was shown to affect membrane
functions in cultured liver cells (40). It is possible,
FIGURE 3. Iron-resistant focus illustrated in Fig. 2. Iron reac-
tion, x 125.
therefore, that the action of phenobarbital may be
mediated both by its interaction with cell mem-
branes and its effect on gene expression giving rise
to alterations in the composition of liver cell mem-
branes. Relatively little is known about the factors
that regulate permeability of gap junctions. It has
been shown by Rose et al. (41) that ionic calcium
produces a graded decrease in permeability. Sev-
eral studies (42, 43) have now shown that phorbol
ester promoters alter the permeability of mem-
branes to calcium. The effect of liver tumor pro-
moters such as DDT and phenobarbital on intracell-
ular calcium levels has not been studied, but it is
possible that their inhibition of intercellular commu-
nication could be mediated through such an action.
Other effects by surface active substances which
would inhibit intercellular communication can also
be conceived.
Promotion as the Mechanism of
Carcinogenicity of Certain
Epigenetic Hepatocarcinogens
Several organochlorine compounds and drugs
produce primarily or exclusively liver tumors in ro-
dents under conditions of prolonged administration
at high levels (Table 3). The properties of these sub-
stances differ significantly from those of the more
thoroughly studied carcinogens described by Miller
and Miller (44) as giving rise to reactive electro-
philes; the latter are sometimes effective with a sin-
gle exposure, are often active at low doses, and gen-
erally produce neoplasms in high yield, at multiple
sites, and usually after short or moderate latent
periods. In part because of such differences in the
carcinogenic effects between diverse carcinogens,
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FIGURE 4. Effect of phenobarbital on persistence of liver al-
tered foci induced by N-2-fluorenylacetamide.
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Phenobarbital + + + /-
Barital + + NT
Clofibrate NT +
Nafenopin + + +
DDT + +
Dieldrin + +
Lindane + + +/-
Mirex + + +
Polychlorinated biphenyls + + +
a+ +indicates more active than +; - is negative; +i-
mostly negative studies; NT not tested.
cinogens, genotoxic and epigenetic was proposed
(45, 46). In this classification, genotoxic carcinogens
are defined as those that are capable of producing
DNA damage through formation of covalent bonds
and thus, correspond to carcinogens that act as elec-
trophilic reactants. Epigenetic carcinogens are de-
fined as those that do not damage DNA but rather,
act by indirect mechanisms. The genotoxicity of car-
cinogens can be evaluated by determinaton of their
ability to chemically modify DNA or produce gen-
etic damage in short-term tests. Substantial evi-
dence from the evaluation in tests for genetic dam-
age by the hepatocarcinogenic chemicals in Table 3
indicates a lack of genotoxic action (18). Therefore,
such chemicals have been suggested to be epige-
netic carcinogens, probably of the promoter class
(18, 47). Consistent with this concept, several of
these carcinogens such as phenobarbital and DDT
(48) have been shown to enhance the carcinogenic ef-
fect of previously administered genotoxic carcino-
gens under conditions in which the proposed epi-
genetic carcinogens are not carcinogenic by them-
selves. This effect in sequential administration is
usually interpreted as evidence of promoting ac-
tivity, although in the absence of other information,
it could equally well represent a summation of mul-
tiple genotoxic effects (49). Nevertheless, the lack of
genotoxicity combined with the ability to inhibit in-
tercellular communication indicates that the en-
hancing effect of these chemicals on hepatocarcino-
genicity is due to a promoting action.
The ability of chemicals of this type to produce
tumors in the livers of certain rodent strains may
be due to their action on altered liver cells that
arise spontaneously, through inherited genetic de-
fects or through the action of occult viruses or car-
cinogens. The presence of such cells is indicated by
the development of altered foci in nontreated ani-
mals (50, 51) and the development of noninduced
liver tumors (52-55). Such abnormal cells could be
released for progressive growth as neoplasms by in-
terference with the transmission of regulatory fac-
tors from normal cells as result of inhibition of inter-
cellular communication (24). This concept would ex-
plain certain of the dose-response characteristics of
carcinogens of this type. Such carcinogens would
have to be administered in a sufficiently high dose
to extensively alter the cell membrane, either
through accumulation in the lipid layer as with DDT
or through alteration of the membrane composition
as with phenobarbital, in order to inhibit intercellu-
lar exhange at the many sites of communication be-
tween cells. In addition, such chemicals would have
to be administered for a sufficient duration in order
to enable the altered cells either to achieve a suffi-
cient mass to insulate themselves from regulatory
signals transmitted by the normal tissue or to ac-
quire additional abnormalities during proliferation
that would enable them to become resistant to in-
tercellular communication.
Implications for Health Risk
Analysis
The evidence is growing to implicate promoting
agents in the etiology of human cancer. Indeed, the
main cancers in the U.S., i.e., cancers of the lung,
colon and breast, each appear to be determined in a
distinct way by the tumor-promoting effects pro-
duced by either cigarette smoking or consumption
of a diet high in fat (56, 57). Importantly, however,
such agents with promoting action are self-imposed
at high levels and for prolonged periods. In con-
trast, most uses of the synthetic chemicals of the
promoting class of epigenetic hepatocarcinogens dis-
cussed above do not result in high levels of human
exposure. Moreover, exposure to these agents, even
where it has been substantial as in the case of phe-
nobarbital, has not been found to lead to an in-
creased incidence of cancer (58, 59). Several explana-
tions may account for the lack of an effect in hu-
mans. Perhaps most likely is the possibility that hu-
man exposures are too low or of insufficient dura-
tion to achieve promotion according to the concepts
presented here. Additionally, if human cells were
more competent than rodent cells in intercellular
communication, then exposures would have to be
even greater than in the animal studies to effect
promotion. Finally, the low incidence of liver neo-
plasms in most population groups suggests that hu-
mans, in contrast to animals, such as certain mouse
strains in particular, do not have a background of
initiated cells in the liver upon which promoters can
operate. Thus, the evidence supports the conclusion
that liver tumor promoters, like certain other epige-182 G. M. WILLIAMS
netic carcinogens, such as hormones, are not hazar-
dous at low levels of exposure.
The concepts on mechanism of action of pro-
moters described herein led to the suggestion by
Weisburger and Williams (60) that the risk analysis
for epigenetic carcinogens of this type should be dif-
ferent from that of genotoxic carcinogens. The lat--
ter, because of their capacity to directly modify
genetic material, should be considered a hazard at
any significant level of exposure, although even
with these carcinogens metabolic detoxification and
DNA repair processes together with the low proba-
bility of producing the critical alteration in DNA at
a low level of exposure, indicate that thresholds
should exist. With epigenetic agents, because of the
nature of the underlying mechanisms, thresholds
probably occur even at significant levels of expo-
sure.
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